m for p with L858R in both tumor and serum (P = 0.13). In the multivariate analysis, male gender, L858R and the presence of mEGFR in serum were independent factors for poor prognosis (Table). MS was 31 m for p with mEGFR only in tumor and 28 m for p with mEGFR in tumor and serum (P = 0.21). When only the 97 p with mEGFR in both tumor and serum were analyzed, p with L858R were older than those with del 19 (73 vs 63 years, respectively; P = 0.01). Response rate was higher in p with del 19 (78.3%) than in p with L858R (59.4%) (P = 0.05). TTP for p with del 19 was 13 m vs 11 m for p with L858R (P = 0.07). MS for p with del 19 was 31 m vs 18 m for p with L8585R (P = 0.01).

Conclusions: mEGFR in serum could be an ancillary non-invasive method for genotyping when there is insufficient tumor tissue. The presence of mEGFR in serum is a prognostic marker for shorter TTP.

	HR	95% CI	p
Sex			
Female	1 (ref.)		
Male	2.39	0.39−0.93	0.001
Exon			
19	0.55	0.36−0.85	0.008
21	1 (ref.)		
Serum (EGFR)			
WT	1 (ref.)		
Mutated	1.63	1.05−2.55	0.03

9001 ORAL

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

W.E.E. Eberhardt[1], B.E. Johnson[2], Y. Sun[3], P. Germonpré[4], N. Saijo[5], C. Zhou[6], J. Wang[7], H. Tada[8], S.J. Kennedy[9], R.S. Herbst[10]. *[1]West German Tumor Center University Duisburg-Essen, Medicine (Cancer Research), Essen, Germany; [2]Dana-Farber Cancer Institute, Medical Oncology, Boston, USA; [3]Cancer Hospital, Medical Oncology, Beijing, China; [4]Antwerp University Hospital, Pulmonary Medicine, Antwerp, Belgium; [5]National Cancer Center Hospital East, Thoracic Oncology, Chiba, Japan; [6]Tongji University, Oncology, Shanghai, China; [7]Beijing Institute for Cancer Research, Oncology, Beijing, China; [8]AstraZeneca, Medical Science, Wilmington, USA; [9]AstraZeneca, Biostatistics, Macclesfield, United Kingdom; [10]University of Texas MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, Houston, USA*

Background: Vandetanib (ZACTIMA™) is a once-daily oral inhibitor of VEGFR, EGFR and RET signalling. The addition of vandetanib 100 mg/day to docetaxel (doc) prolonged progression-free survival (PFS) in a randomized phase II study in patients with previously treated advanced NSCLC (Heymach *et al*, JCO 2007).

Methods: The primary objective of this phase III study (ZODIAC; D4200C00032) was to determine whether vandetanib 100 mg/day+doc 75 mg/m^2 every 21 days (max 6 cycles) prolonged PFS vs placebo + doc. Secondary endpoints included overall survival (OS), objective response rate (ORR), time to deterioration of symptoms (TDS) and safety. Efficacy and safety in females were assessed as a co-primary analysis population. Eligibility criteria included stage IIIB/IV NSCLC, performance status (PS) 0−1 and previous chemotherapy.

Results: Between May 06−April 08, 1391 patients (mean age, 58 yrs; 30% female; 25% squamous; 10% brain mets; 85% stage IV; 35%/65% PS 0/1) were randomized to vandetanib+doc (n = 694) or placebo+doc (n = 697). Baseline characteristics were similar in both arms. At data cut-off, the median duration of follow-up was 12.8 months, 87% patients had progressed and 59% had died. The addition of vandetanib to doc showed a statistically significant improvement in PFS vs doc (hazard ratio [HR] 0.79, 97.58% CI 0.70−0.90; 2-sided $P < 0.001$), and a similar advantage in females (HR 0.79; 2-sided $P = 0.024$). Significant advantages for vandetanib + doc were also seen for ORR (17% vs 10%, 2-sided $P < 0.001$) and TDS (HR 0.77, 2-sided $P < 0.001$; FACT-L Lung Cancer Subscale). OS showed a positive trend for vandetanib+doc that was not statistically significant (HR 0.91, 97.52% CI 0.78−1.07; 2-sided $P = 0.196$). Exploratory clinical and molecular subgroup analyses for PFS and OS were generally consistent with the results seen in all patients. The adverse event profile was consistent with that previously observed for vandetanib in NSCLC. The vandetanib arm had a higher incidence of diarrhoea (42% vs 33%), rash (42% vs 24%), neutropenia (32% vs 27%) and hypertension (6.0% vs 1.7%). Nausea (23% vs 32%), vomiting (16% vs 21%) and anaemia (10% vs 15%) were less frequent in the vandetanib arm. The incidence of protocol-defined QTc prolongation in the vandetanib arm was 1.9%.

Conclusions: This study met its primary objective of PFS prolongation with vandetanib+doc vs doc alone. Vandetanib is the first and only targeted therapy to show significant clinical benefits when added to chemotherapy in phase III studies in second-line advanced NSCLC. An OS update will be performed in 2009.

9002 ORAL

A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405

J. Tsurutani[1], T. Mitsudomi[2], S. Mori[3], I. Okamoto[1], N. Kaname[4], H. Tada[5], S. Negoro[6], Y. Yatabe[7], M. Fukuoka[8], K. Nakagawa[1]. *[1]Kinki University School of Medicine, Medical Oncology, Osakasayama, Japan; [2]Aichi Cacer Center, Thoracic Oncology, Nagoya, Japan; [3]Yokohama City University, Biostatistics and Epidemiology, Yokohama, Japan; [4]National Kyushu Cancer Center, Thoracic Oncology, Fukuoka, Japan; [5]Osaka City General Hospital, Thoracic Oncology, Osaka, Japan; [6]Hyogo Cancer Center, Medical Oncology, Akashi, Japan; [7]Aichi Cancer Center, Pathology and Molecular Diagnostics, Nagoya, Japan; [8]Kinki University School of Medicine Sakai Hospital, Medical Oncology, Sakai, Japan*

Background: Patients with non-small cell lung cancer (NSCLC) harboring activating mutations of the EGFR gene respond remarkably well to EGFR specific tyrosine kinase inhibitor, gefitinib. However, its superiority to standard platinum doublet chemotherapy in terms of progression free survival (PFS) or overall survival (OS) is not known.

Material and Methods: Chemo naive patients with stage IIIB/IV or recurrent NSCLC, harboring activating EGFR mutation (either exon 19 deletion or L858R in exon 21) aged 75 years or younger, with PS of 0 or 1 were enrolled. Patients were randomized to receive either gefitinib (250 mg/day) until progression or cisplatin (80 mg/sqm) plus docetaxel (60 mg/sqm) day 1, given every 21 days for three cycles to six cycles. PFS was the primary endpoint. Assuming that PFS for gefitinib was 12.5months and for chemotherapy was 7 month based on the previous reports, hazard ratio would be 0.56. With this HR, 146 patients would be required to have a power of 0.8. However, sample size was set at 200 patients to allow HR up to 0.64.

Results: As of April 25, 164 patients had been randomized. Here, we report the preliminary data for 122 patients of the 164. Of 122, 55 patients were postoperative recurrence and 67 were with stage IIIB/IV diseases. Age, sex, stage, smoking history and absence or presence of postoperative adjuvant chemotherapy were well balanced between two groups. Percentages of the patients with age of 65 or older, female, non-smokers were 49%, 74%, and 75%, respectively. For all patients, median PFS was 8.4 months and one-year PFS rate was 32.4% (95% confidence interval (CI); 22.4−42.9%). Median survival was not reached and one-year OS rate was 94.0% (95% CI; 84.7−97.7%).

Conclusions: The enrollment of this phase III trial is ongoing. NSCLC patients with EGFR mutations had good prognosis irrespective of the treatments confirming the previous reports. Subset analysis of IPASS (Phase III study of gefitinib vs. carboplatin/paclitaxel in Asian, non-/light smokers with adenocarcinoma of the lung) suggested that NSCLC patients with EGFR mutation treated with gefitinib had a significantly longer PFS than those treated with chemotherapy with a HR of 0.48 (~10 months vs. ~6 months). Our study appears to have similar PFS and it would be positive if this HR is reproduced. Data on response rates and safety profile will be available at the presentation. The final analysis is expected in early 2010.

9003 ORAL

Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer

M. Kris[1], T. Mok[2], E. Kim[3], J.Y. Douillard[4], M. Fukuoka[5], N. Thatcher[6]. *[1]Memorial Sloan-Kettering Cancer Center, New York, USA; [2]The Chinese University of Hong Kong, Hong Kong, China; [3]The University of Texas M.D. Anderson Cancer Center, Houston, USA; [4]Centre René Gauducheau, Nantes, France; [5]Kinki University School of Medicine, Osaka, Japan; [6]Christie Hospital, Manchester, United Kingdom*

Background: Gefitinib (Iressa®) inhibits tyrosine kinase activity of the epidermal growth factor receptor (EGFR). The EGFR kinase can be constitutively activated by mutations in exon 19 or 21 of the *EGFR* gene. Cells harboring these mutations are “addicted” to EGFR signaling and are exquisitely sensitive to blockade of the kinase. These mutations are often found in the tumors of patients (pts) with marked benefit to gefitinib. We